BEAM
Beam Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.19
+3.07%Year over year
Reported trailing growth
- Revenue
- +158.9%
- EBITDA
- +84.0%
- EBIT
- +15.2%
- EPS
- +81.8%
- Free cash flow
- -4.8%
- Operating cash flow
- -4.2%
Forward estimates
Based on analyst estimates
- Revenue
- -66.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +31.9%
- EBITDA
- +96.1%
- EBIT
- +7.7%
- Net income
- +78.8%
- EPS
- +82.3%
- Free cash flow
- -1.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026